Novo Nordisk acquires Ziylo in $800m deal to advance diabetes treatment
Novo Nordisk, a leading Danish pharmaceutical company, has completed a significant acquisition of Ziylo, a biotechnology spin-out from the University of Bristol, for a deal potentially worth over $800 million. This acquisition grants Novo Nordisk full rights to Ziylo’s innovative glucose binding molecules, crucial for the development of glucose responsive insulins. Strategic Importance of the […]